ClinicalTrials.gg
Active, not recruitingNCT04925752PURPOSE 2Updated Oct 6, 2026Results posted

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

A Phase 3 interventional study of Oral Lenacapavir (LEN) and F/TDF in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 93 sites in 8 countries. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Prevention

Updated Oct 6, 2026Study documents postedPosted results revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,292
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in HIV Infections by Gilead Sciences — 2 open to participants now, 8 under way, 4 of them phase 3. HIV Infections · Gilead Sciences.

Enrollment
2nd of 72
3,292 · median 131
Started
2021
with 1 other
Phase 3
26 of 84
1 open now
Registered
78th of 84
by date

Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 2nd largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 78th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 84 studies in HIV Infections by Gilead Sciences are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in HIV Infections by Gilead Sciences, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.

The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

03

Conditions studied

  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Incidence Phase

  • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for infection.
  • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.
  • Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

    • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
    • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
    • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

  • Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated (eGFR) ≥ 60 mL/min at screening according to the formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

  • Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
  • Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

  • Acute viral hepatitis A, B or C or evidence of chronic or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,292 participants (actual)

Study arms

  • Experimental
    Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

    Participants will receive the following for up to approximately 52 weeks: * Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks * Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily * Oral LEN 600 mg on Days 1 and 2 Participants will receive oral LEN if SC injections are not available.

    Drug: Oral Lenacapavir (LEN) · Drug: Sub-cutaneous (SC) Lenacapavir (LEN) · Drug: PTM F/TDF

  • Experimental
    Randomized Blinded Phase: Placebo LEN + F/TDF

    Participants will receive the following for up to approximately 52 weeks: * SC LEN placebo every 26 weeks * Oral F/TDF 200/300 mg once daily * PTM Oral LEN on Days 1 and 2 Participants will receive oral LEN placebo if SC injections are not available.

    Drug: F/TDF · Drug: Placebo SC LEN · Drug: PTM Oral LEN

  • Experimental
    LEN Open-Label Extension (OLE) Phase

    Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2. All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first. After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.

    Drug: Oral Lenacapavir (LEN) · Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

  • Experimental
    Pharmacokinetic (PK) Tail Phase

    Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days). Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.

    Drug: F/TDF · Drug: F/TAF (for US participants only)

Interventions

  • Tablets administered orally without regard to food

    Also known as: GS-6207

  • DrugF/TDF

    Tablets administered orally

    Also known as: Truvada®

  • DrugSub-cutaneous (SC) Lenacapavir (LEN)

    Administered via SC injections

    Also known as: GS-6207; Yeztugo

  • DrugPlacebo SC LEN

    Administered via SC injections

  • DrugPTM F/TDF

    Tablets administered orally

  • DrugPTM Oral LEN

    Tablets administered orally

  • DrugF/TAF (for US participants only)

    Drug page: Emtricitabine tenofovir alafenamide

    F/TAF tablets administered orally once daily

    Also known as: Descovy

06

What researchers measure

Primary outcomes

  1. Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)

    bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.

    Time frame: Incidence Phase Screening Visit (Day 1)

  2. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)

    HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

    Time frame: Up to 149 weeks

Secondary outcomes

  1. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF

    HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

    Time frame: Up to 149 weeks

  2. Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN

    A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

    Time frame: Up to 149 weeks

  3. Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

    Time frame: First dose date up to 184 weeks

  4. Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

    Time frame: First dose date up to 184 weeks

07

Results

Posted Sep 17, 2025

Participant flow

4807 participants were screened. Out of 4807, 4634 had at least 1 non-missing HIV-1 diagnosis based on HIV test results from a central laboratory. So, 4634 participants were considered for screening in Incidence Phase and were included in All Screened Set. Out of 4634, 3292 were enrolled and randomized in Randomized Blinded Phase. Incidence Phase refers to Screening Phase. Participants were enrolled in Argentina, Brazil, Mexico, Peru, Puerto Rico, South Africa, Thailand and the United States.

Randomized Blinded Phase
Participant flow — Randomized Blinded Phase
MilestoneRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFOpen-Label Extension (OLE) Phase: LENOLE Phase: F/TDF
Started2195109700
Completed180890600
Not completed38719100
Withdrew: Lost to follow-up1787800
Withdrew: Withdrew consent1527300
Withdrew: Randomized but never treated12900
Withdrew: Hiv-1 infection61100
Withdrew: Investigator's discretion19800
Withdrew: Non-compliance with study drug8500
Withdrew: Adverse event6200
Withdrew: Death5200
Withdrew: Protocol violation1300
OLE Phase (LEN OLE and PK Tail Phases)
Participant flow — OLE Phase (LEN OLE and PK Tail Phases)
MilestoneRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFOpen-Label Extension (OLE) Phase: LENOLE Phase: F/TDF
Started001797863
Completed0000
Not completed001797863

Outcome measures

PrimaryIncidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.

Time frame:
Incidence Phase Screening Visit (Day 1)
Reported as:
Number · HIV-1 events per 100 person-years
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
HIV-1 events per 100 person-yearsIncidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)2.374 (1.649 to 3.417)
PrimaryRandomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)

HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Time frame:
Up to 149 weeks
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
HIV-1 events per 100 person-yearsRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFIncidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)0.103 (0.012 to 0.373)2.374 (1.649 to 3.417)
Statistical analysis
  • Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Wald test · p = <0.0001 (p-value for rate ratio vs bHIV is from Wald test.) · Rate ratio: 0.043 · 95% CI 0.010 to 0.182Confidence Interval (CI) for rate ratio vs bHIV is based on the delta method.
  • Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Wald test · p = < 0.0001 (p-value for rate ratio vs bHIV is from Wald test.) · Rate ratio: 0.043 · 95% CI 0.010 to 0.182CI for rate ratio vs bHIV is based on the delta method.
SecondaryRandomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Time frame:
Up to 149 weeks
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
HIV-1 events per 100 person-yearsRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDF
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF0.103 (0.012 to 0.373)0.931 (0.426 to 1.768)
Statistical analysis
  • Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF vs Randomized Blinded Phase: Placebo LEN + F/TDF · Hybrid approach · p = <0.0001 (p-value for rate difference (SC LEN minus F/TDF) is based on a hybrid approach.) · Rate difference: -0.828 · 95% CI -1.669 to -0.255Exact CI for rate difference versus F/TDF is based on a hybrid approach.
  • Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF vs Randomized Blinded Phase: Placebo LEN + F/TDF · Poisson model · p = 0.00245 (P-value for rate ratio versus F/TDF is from a Poisson model.) · Rate ratio: 0.111 · 95% CI 0.024 to 0.513Confidence interval for rate ratio versus F/TDF is from a Poisson model.
SecondaryRandomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Time frame:
Up to 149 weeks
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
HIV-1 events per 100 person-yearsRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN0.125 (0.015 to 0.452)
SecondaryRandomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

Time frame:
First dose date up to 184 weeks
Reported as:
Number · percentage of participants
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDF
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)94.591.6
SecondaryRandomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

Time frame:
First dose date up to 184 weeks
Reported as:
Number · percentage of participants
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
percentage of participantsRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDF
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities15.016.5

Adverse events

Collected over All-Cause Mortality: Up to 223 weeks; Adverse Events: Up to 184 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF5/2,195 (0.2%)96/2,183 (4.4%)1,950/2,183 (89.3%)
Randomized Blinded Phase: Placebo LEN + F/TDF2/1,097 (0.2%)56/1,088 (5.1%)905/1,088 (83.2%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDF
AppendicitisInfections and infestations7/21836/1088
Suicide attemptPsychiatric disorders11/21834/1088
Suicidal ideationPsychiatric disorders3/21835/1088
AnxietyPsychiatric disorders0/21833/1088
Hepatitis AInfections and infestations5/21831/1088
Major depressionPsychiatric disorders1/21832/1088
Acute myocardial infarctionCardiac disorders3/21830/1088
PneumoniaInfections and infestations3/21831/1088
DepressionPsychiatric disorders3/21831/1088
VertigoEar and labyrinth disorders0/21831/1088
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRandomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDF
Injection site noduleGeneral disorders1432/2183443/1088
Injection site painGeneral disorders1299/2183609/1088
Injection site erythemaGeneral disorders394/2183218/1088
Injection site indurationGeneral disorders362/2183115/1088
Anal chlamydia infectionInfections and infestations351/2183156/1088
Oropharyngeal gonococcal infectionInfections and infestations344/2183143/1088
Anal gonococcal infectionInfections and infestations288/2183124/1088
Injection site swellingGeneral disorders155/2183105/1088
Upper respiratory tract infectionInfections and infestations169/218390/1088
DiarrhoeaGastrointestinal disorders161/218383/1088

Baseline characteristics

The Randomized Blinded Phase Safety Analysis Set included all participants who took at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
Mean30 ± 8.731 ± 9.530 ± 9.0
Age, Customized
Age, Customized(Participants)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
16 to <18 years314
18 to ≤ 25 years7493431092
> 25 to < 35 years9124231335
35 to < 50 years454267721
≥ 50 years6554119
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
Female432467
Male214010643204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
Race — White7233441067
Race — Black or African American583301884
Race — Other or More Than One Race578285863
Race — Asian269144413
Race — American Indian or Alaska Native191231
Race — Not Collected8210
Race — Native Hawaiian or Other Pacific Islander303
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
Ethnicity — Hispanic or Latino13786752053
Ethnicity — Not Hispanic or Latino8044131217
Ethnicity — Not Collected101
Region of Enrollment
Region of Enrollment(Participants)Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFRandomized Blinded Phase: Placebo LEN + F/TDFTotal
Puerto Rico9211
Argentina16164225
United States431233664
Brazil7693961165
South Africa246112358
Mexico8412
Thailand250139389
Peru309138447
08

Study locations

93 sites
  • UAB Sexual Health Research Clinic
    Birmingham, Alabama 35233, United States
  • Loma Linda University Clinical Trial Center Clinic
    Loma Linda, California 92354, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • UCLA CBAM Vine Street Clinic
    Los Angeles, California 90038, United States
  • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
    Los Angeles, California 90059, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Los Angeles, California 90502, United States
  • BIOS Clinical Research
    Palm Springs, California 92262, United States
  • UCSD Anti Viral Research Center
    San Diego, California 92103, United States
  • Bridge HIV at the San Francisco Department of Public Health
    San Francisco, California 94102, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • University of Colorado Clinical and Translational Research Centers (CTRC)
    Aurora, Colorado 80045, United States
  • Yale University, School of Medicine
    New Haven, Connecticut 06510, United States
  • Whitman-Walker Institute Inc.
    Washington D.C., District of Columbia 20009, United States
  • Washington Health Institute
    Washington D.C., District of Columbia 20017, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary Richmond, MD, PA
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology & Research Center, LLC
    Ft. Pierce, Florida 34982, United States
  • CAN Community Health Clinic
    Jacksonville, Florida 32207, United States
  • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
    Miami, Florida 33136, United States
  • CAN Community Health
    Miami Gardens, Florida 33055, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • CAN Community Health
    Sarasota, Florida 34237, United States
  • The Hope Clinic at Emory University
    Atlanta, Georgia 30030, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • Emory University Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
  • RMR Core Center
    Chicago, Illinois 60612, United States
  • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
    Chicago, Illinois 60612, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Indiana University Infectious Diseases Research
    Indianapolis, Indiana 46202, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Norton Infectious Disease Specialists
    Louisville, Kentucky 40241, United States
  • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
    New Orleans, Louisiana 70119, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • The Fenway Institute
    Boston, Massachusetts 02215, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Open Arms Healthcare Center
    Jackson, Mississippi 39202, United States
  • KC CARE Health Center
    Kansas City, Missouri 64111, United States
  • St. Michael's Medical Center
    Newark, New Jersey 07102, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
    New York, New York 10029, United States
  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Cone Health/Regional Center for Infectious Disease Research Center
    Greensboro, North Carolina 27401, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Penn Prevention Unit
    Philadelphia, Pennsylvania 19104, United States
  • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina, Infectious Disease Clinic
    Charleston, South Carolina 29425, United States
  • Prisma Health-Midlands Clinical Research Unit
    Columbia, South Carolina 29203, United States
  • Prisma Health Internal Medicine Clinic
    Greenville, South Carolina 29605, United States
  • Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
    Memphis, Tennessee 38103, United States
  • St Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Meharry Medical College Clinical and Transitional Research Center
    Nashville, Tennessee 37208, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Centro San Vincente
    El Paso, Texas 79915, United States
  • UT Health Science Center at Houston
    Houston, Texas 77009, United States
  • The Crofoot Research Center, INC
    Houston, Texas 77098, United States
  • Ofiice of Dr. Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Hospital General de Agudos JM Ramos Mejia
    Buenos Aires, 1072, Argentina
  • Fundacion Huesped
    Buenos Aires, 1202, Argentina
  • Instituto de Investigaciones Clinicas Mar del Plata
    Buenos Aires, B7600, Argentina
  • Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
    Belo Horizonte - MG, 30130-100, Brazil
  • Fundação Bahiana de Infectologia
    Canela-Salvador, 40110-060, Brazil
  • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
    Manauas, 69040-000, Brazil
  • Hospital General de Nova Iguaçu - HGNI
    Nova Iguaçu, 26030-380, Brazil
  • Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
    Porto Alegre, RS 91350 200, Brazil
  • Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
    Rio de Janeiro, 21040-360, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, 01246-903, Brazil
  • Centro de Referência e Treinamento DST/AIDS
    São Paulo, 04121-000, Brazil
  • Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
    São Paulo, 06519-332, Brazil
  • Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
    Guadalajara C.P., 44160, Mexico
  • Asociacion Civil Impacta Salud y Educacion - Sede Barranco
    Barranco, 15063, Peru
  • Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
    Callao, 7006, Peru
  • Asociacion Civil Selva Amazonica
    Iquitos, Peru
  • Via Libre
    Lima, 15001, Peru
  • Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
    Lima, 15088, Peru
  • Ararat Research Center
    San Juan, PR 00717, Puerto Rico
  • Centro Ararat- San Juan
    San Juan, PR 00909, Puerto Rico
  • Desmond Tutu Health Foundation
    Cape Town, 7925, South Africa
  • Wits Reproductive Health and HIV Institute (Wits RHI)
    Johannesburg, 2038, South Africa
  • The Aurum Institute: Pretoria Clinical Research Centre
    Pretoria, 87, South Africa
  • Setshaba Research Centre
    Soshanguvhe, 0152, South Africa
  • The Aurum Institute Tembisa CRC, Clinic 4
    Tembisa, 1632, South Africa
  • FPD-DTHF Ndevana Commuity Research Site
    Vincent, 5217, South Africa
  • Institute of HIV Research and Innovation
    Bangkok, 10330, Thailand
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
    Bangkok, 10330, Thailand
  • Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Research Institute for Health Sciences, Chiang Mai University
    Chiang Mai, 50200, Thailand
  • Srinagarind Hospital, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Bamrasnaradura Infectious Disease Institute
    Nonthaburi, 11000, Thailand
09

References and documents

Publications

  • Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2). Presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, United Kingdom.
  • Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sanchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. PubMed 39602624 ↗
  • Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS One. 2022 Jun 3;17(6):e0267780. doi: 10.1371/journal.pone.0267780. eCollection 2022. PubMed 35657826 ↗
  • Cantos Lucio VD, Mngadi K, Supparatpinyo K, et al. From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2026); February 22-25, 2026; Denver, CO. Abstract 129.
  • Kwan TH, Chan DPC, Lee SS. Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study. BMC Public Health. 2025 Dec 26;26(1):361. doi: 10.1186/s12889-025-26025-5. PubMed 41449429 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Aug 2024, 37 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 37 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 14, 2021
StartActual
Jun 28, 2021
Primary completionActual
Aug 21, 2024
CompletionEst.
Aug 2028
Results first posted
Sep 17, 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 6, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedRandomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 4 years → First dose date up to 184 weeks
  • EditedRandomized Blinded Phase: Percentage of Participants Experiencing Clinically SignificantGrade 3 or Higher Laboratory AbnormalitiesTime frame: Up to 4 years → First dose date up to 184 weeks
Oct 6, 2026
Title
Pre-Exposure Prophylaxis Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People Who Are at Risk for HIV Infection
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Posted results revised
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedRandomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 4 years → First dose date up to 184 weeks
    • EditedRandomized Blinded Phase: Percentage of Participants Experiencing Clinically SignificantGrade 3 or Higher Laboratory AbnormalitiesTime frame: Up to 4 years → First dose date up to 184 weeks
    Title Pre-Exposure Prophylaxis Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People Who Are at Risk for HIV Infection
    + 3 other changes: verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04925752
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Jun 28, 2021
Primary completion
Aug 21, 2024
Completion
Aug 2028 (estimated)
Results posted
Sep 17, 2025
Last update
Oct 6, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenacapavir · Emtricitabine tenofovir alafenamide

Start the discussion